ZA936872B - 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-B]heterocyclic-2-one useful in the treatment of cognitive disorders of man - Google Patents

3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-B]heterocyclic-2-one useful in the treatment of cognitive disorders of man

Info

Publication number
ZA936872B
ZA936872B ZA936872A ZA936872A ZA936872B ZA 936872 B ZA936872 B ZA 936872B ZA 936872 A ZA936872 A ZA 936872A ZA 936872 A ZA936872 A ZA 936872A ZA 936872 B ZA936872 B ZA 936872B
Authority
ZA
South Africa
Prior art keywords
pyrrolo
disubstituted
dihydro
heterocyclic
man
Prior art date
Application number
ZA936872A
Other languages
English (en)
Inventor
Wendell Wilkie Wilkerson
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of ZA936872B publication Critical patent/ZA936872B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA936872A 1992-09-18 1993-09-17 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-B]heterocyclic-2-one useful in the treatment of cognitive disorders of man ZA936872B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/947,152 US5278162A (en) 1992-09-18 1992-09-18 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man

Publications (1)

Publication Number Publication Date
ZA936872B true ZA936872B (en) 1995-03-17

Family

ID=25485622

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA936872A ZA936872B (en) 1992-09-18 1993-09-17 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-B]heterocyclic-2-one useful in the treatment of cognitive disorders of man

Country Status (10)

Country Link
US (1) US5278162A (de)
EP (1) EP0660833A1 (de)
JP (1) JPH08501550A (de)
CN (1) CN1094406A (de)
AU (1) AU4856893A (de)
CA (1) CA2144636A1 (de)
IL (1) IL107003A0 (de)
TW (1) TW248560B (de)
WO (1) WO1994006793A1 (de)
ZA (1) ZA936872B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296478A (en) * 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
US5854232A (en) * 1994-04-29 1998-12-29 Pfizer Inc. Acyclic anc cyclic amides as neurotransmitter release enhancers
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
JP5460324B2 (ja) * 2006-10-12 2014-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド 治療剤としてのスピロ−オキシインドール化合物の使用
BRPI0719166A2 (pt) * 2006-10-12 2014-06-03 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
DK2350090T3 (en) * 2008-10-17 2015-09-07 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
EP2350091B1 (de) * 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindol verbindungen und ihre verwendung als therapeutische wirkstoffe
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047174A1 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
EP0419561A1 (de) * 1988-06-14 1991-04-03 Schering Corporation Heterobicyclische verbindungen mit antientzündungsaktivität
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones

Also Published As

Publication number Publication date
JPH08501550A (ja) 1996-02-20
EP0660833A1 (de) 1995-07-05
AU4856893A (en) 1994-04-12
TW248560B (de) 1995-06-01
CA2144636A1 (en) 1994-03-31
US5278162A (en) 1994-01-11
IL107003A0 (en) 1993-12-28
CN1094406A (zh) 1994-11-02
WO1994006793A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
ZA948592B (en) 7H-imidazo[1,2-a]pyrazin-8-one derivatives,and their preparation and use
GR3017877T3 (en) Pharmaceutical compounds.
ZA936872B (en) 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-B]heterocyclic-2-one useful in the treatment of cognitive disorders of man
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
OA09362A (en) "Production and use of porphyrins".
ZA904991B (en) 5,11-dihydro-6h-dipyrido(3,2-b:2',3'-e)(1,4)-diazepin-6-ones and-thiones and their use for the treatment of aids
EP0275668A3 (en) Use of ketone derivatives in the treatment of cognitive disorders
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
GB2222362B (en) "swivel wheel assembly"
IL104755A0 (en) Treatment of glaucoma
AU4096789A (en) The use of lactam derivatives in the treatment of cognitive disorders
SG47098A1 (en) Diamines in the treatment of arrhythmia
GB2185255B (en) Pyrazolo [4,3-c] isoquinolines
GB2282529B (en) Baby's bath
GB2270313B (en) 1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof
ZA937604B (en) 3,3-disubstituted tri and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
ZA893606B (en) Use of diazepinones for treating disorders of the microcirculation
AU2153092A (en) Spirofurane derivatives and their use in the treatment of neurological disorders
GB9607420D0 (en) Formulations of mannose phosphates useful in the treatment of fibrotic disorders
PT84524A (en) Pyrido ]4,3-b" ]1,6"naphthyridine-derivatives process for theirmanufacture and use thereof
KR100199834B1 (en) Tetrahydroisoquinolinylcarbamates of 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indole
ZA894504B (en) Use of 5,11-dihydro-6h-pyrido(2,3-b)(1,4)benzodiazepin-6-ones substituted in the 11-position
AU627874B2 (en) Amino-benzenesulfonamides in the treatment of glaucoma